Автор:
Nazarov VD, Lapin SV, Mazing AV, Evdoshenko EP, Totolian AA.
Год:
2016
Файл:
Загрузить
Публикация: Biochemistry (Moscow), 2016, Vol. 81, No. 11, pp. 1396-1400
Ключевые слова: multiple sclerosis, immunogenicity, interferon-beta, neutralizing antibodies, titer
Аннотация
Multiple sclerosis is a severe autoimmune disease with inflammatory component that continues to be resistant to treatment. One of the approaches retarding its progression is based on using nonspecific therapy with human interferon-beta (IFN-β)-containing pharmaceuticals. Neutralizing antibodies (NAbs) against genetically engineered pharmaceuticals developed by the patient's immune system, which reduce their therapeutic and biological activity, pose a serious problem. Cell lines sensitive to IFN-β activity also quantifying NAb level are applied because direct measurement of IFN-β antiviral activity is complicated. This study was aimed at standardization and validation of a reporter cell system for measuring anti-human IFN-β NAb titers, and evaluation data were obtained with samples from 33 patients with multiple sclerosis.
Процитировать:
Nazarov VD, Lapin SV, Mazing AV, Evdoshenko EP, Totolian AA. Immunogenicity of Human Interferon-Beta-Containing Pharmaceuticals. Biochemistry (Mosc). 2016 Nov;81(11):1396-1400. doi: 10.1134/S000629791611016X . PMID: 27914464.